OXFORD, UK and PHILADELPHIA, PA--(Marketwire - May 31, 2011) - World leaders in image registration, Mirada Medical has developed software tools which bring the power of MR-PET fusion imaging to clinical specialists without the requirement of owning a MR-PET scanner. The new MR-PET workflows in Mirada’s XD3 software, will be showcased by the company at the upcoming Society of Nuclear Medicine (SNM) Annual Meeting June 4th - 7th in San Antonio, Texas.
The unique MR-PET workflow in Mirada’s XD3 oncology software combines fast and powerful tri-modal registration of MR with CT-PET to present a combined diagnostic picture for clinical decision making. Understanding the diverse range of clinical indications that can benefit from combined MR-PET imaging, Mirada worked with interdisciplinary clinical specialists to ensure those key indications and workflows are supported by XD3. An example of this is the diagnostic workflow for staging patients with head and neck cancer, where the diagnostic power of the MR for T staging will be complemented by the metabolic information of the PET images for assessing nodal involvement and distance metastasis. With XD3, users can load all MRI sequences with CT-PET and use validated deformable registration to display fused PET with multiple MR sequences and, if required, an additional multislice CT scan.
CEO Hugh Bettesworth says “Even those with access to a hybrid PET-MR scanner will need powerful software to get most from their cases. For the majority of clinicians who will not be using hybrid equipment, Mirada XD3 will provide exceptional software fusion of their existing reimbursed MRI and PET or CT-PET scans -- all of the benefits, available today, and for a fraction of the price”.
In addition to diagnostic reading and reporting of MR-PET and CT-PET, Mirada will also showcase software which enables simple and elegant presentations to be used at tumor boards. Individual patient cases can be sent directly from the XD3 reading application in only a few clicks via Mirada’s Casemeeting product. Casemeeting is a key time-saving tool for multidisciplinary teams, enabling clinicians or technologists to create information-rich presentations on all cases marked for tumor board. Key images, notes, bookmarks and capability for accessing the complete data set are combined in a ready-to-go presentation, with no need for any other presentation software.
Mirada will be showcasing the new MR-PET software and Casemeeting at booth 4027, during the Society of Nuclear Medicine (SNM) Annual Meeting June 4th - 7th in San Antonio, Texas.
About Mirada Medical
Mirada Medical is an internationally recognized brand in advanced medical imaging. The company develops high value clinical software applications, which are used across diagnostic radiology, nuclear medicine, radiation oncology, tumor board and elsewhere.
Mirada specializes in simplifying technically complex image quantification, allowing clinicians to more confidently diagnose disease, assess response to treatment and plan radiation therapy or surgical intervention.
Mirada was originally spun out of the University of Oxford. The company’s technologies are, to this day, developed by a team of dedicated engineers and world-renowned scientists working out of Oxford, England.
Mirada’s products have been designed to ease the deployment of these powerful technologies into any hospital or imaging center workflow. Mirada’s applications can be delivered using thin client or cloud based architectures, or licensed on a floating or per workstation basis.
Most recently, Mirada has focused on the development of disease specific solutions for use across departments working with patients to fight cancer. In particular, Mirada’s powerful image registration technologies have been tuned to the needs of radiation oncology, and quantification technologies have been redefined to optimize support for standard protocols such as RECIST and PERCIST. In addition, powerful imaging solutions have been introduced to support better collaborative working, in particular in the context of a rich web-based viewer for referring physicians and a robust solution for presentation of images at tumor board.
For more information, please contact:
Mirada Medical
Europe:
Hugh Bettesworth
CEO
tel: +44 (0) 1865 261410
US:
Mary Beth Archibald
EVP US Service and Operations
tel: +1 816 536 8385
enquiries@mirada-medical.com
www.mirada-medical.com